XTX Topco Ltd Acquires New Holdings in Exelixis, Inc. (NASDAQ:EXEL)

XTX Topco Ltd bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 30,949 shares of the biotechnology company's stock, valued at approximately $1,031,000.

Other large investors have also made changes to their positions in the company. Tri Ri Asset Management Corp bought a new stake in Exelixis during the 3rd quarter worth about $4,396,000. Blue Trust Inc. lifted its holdings in Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after buying an additional 8,208 shares during the period. Range Financial Group LLC bought a new position in Exelixis in the fourth quarter valued at approximately $994,000. Allspring Global Investments Holdings LLC raised its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after acquiring an additional 704,786 shares during the last quarter. Finally, Inspire Investing LLC lifted its stake in shares of Exelixis by 25.0% in the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock valued at $1,221,000 after purchasing an additional 7,331 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling

In other news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the sale, the director now directly owns 356,605 shares in the company, valued at $13,479,669. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by company insiders.

Exelixis Trading Down 0.1 %

Shares of EXEL traded down $0.05 during midday trading on Monday, reaching $36.14. The stock had a trading volume of 349,891 shares, compared to its average volume of 2,168,261. The firm has a market cap of $10.12 billion, a PE ratio of 20.42, a P/E/G ratio of 1.13 and a beta of 0.57. The firm has a 50 day simple moving average of $36.44 and a 200-day simple moving average of $34.36. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on EXEL. Brookline Capital Management began coverage on Exelixis in a report on Monday, December 23rd. They issued a "buy" rating for the company. Royal Bank of Canada upped their target price on shares of Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday, March 13th. Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a report on Thursday. Stifel Nicolaus raised their price objective on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research note on Wednesday, February 12th. Finally, JMP Securities reissued a "market outperform" rating and issued a $41.00 target price on shares of Exelixis in a research note on Thursday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.